Multifocal peripheral neuropathy in eosinophilic fasciitisSATSANGI, J; DONAGHY, M.Journal of neurology. 1992, Vol 239, Num 2, pp 91-92, issn 0340-5354Article

Are cytokine gene polymorphisms important in the pathogenesis of inflammatory bowel disease ?SATSANGI, J; JEWELL, D. P.European journal of gastroenterology & hepatology. 1996, Vol 8, Num 2, pp 97-99, issn 0954-691XArticle

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice : analysis of 620 patient-years follow-upLEES, C. W; ALI, A. I; SHAND, A. G et al.Alimentary pharmacology & therapeutics. 2009, Vol 29, Num 3, pp 286-297, issn 0269-2813, 12 p.Article

Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel diseaseLEES, C. W; MAAN, A. K; HANSOTI, B et al.Alimentary pharmacology & therapeutics. 2008, Vol 27, Num 3, pp 220-227, issn 0269-2813, 8 p.Article

The genetic jigsaw of inflammatory bowel diseaseWATTS, D. A; SATSANGI, J.Gut. 2002, Vol 50, pp iii31-iii36, issn 0017-5749, SUP3Conference Paper

Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3KYO, K; PARKES, M; MUTO, T et al.Human molecular genetics (Print). 1999, Vol 8, Num 2, pp 307-311, issn 0964-6906Article

Cytokine gene polymorphisms in inflammatory bowel diseaseLOUIS, E; SATSANGI, J; ROUSSOMOUSTAKAKI, M et al.Gut. 1996, Vol 39, Num 5, pp 705-710, issn 0017-5749Article

Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance - progress and prospectsJONES, G. R; KENNEDY, N. A; LEES, C. W et al.Alimentary pharmacology & therapeutics. 2014, Vol 39, Num 11, pp 1253-1265, issn 0269-2813, 13 p.Article

New IBD genetics: common pathways with other diseasesLEES, C. W; BARRETT, J. C; PARKES, M et al.Gut. 2011, Vol 60, Num 12, pp 1739-1753, issn 0017-5749, 15 p.Article

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitisLEES, C. W; HEYS, D; ARNOTT, I. D. R et al.Alimentary pharmacology & therapeutics. 2007, Vol 26, Num 3, pp 411-419, issn 0269-2813, 9 p.Article

Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. CommentaryOGURA, Y; LALA, S; GREENSON, J. K et al.Gut. 2003, Vol 52, Num 11, pp 1533-1535, issn 0017-5749, 10 p.Article

Inflammatory bowel disease and the X chromosomeHAYWARD, P. A. R; SATSANGI, J; JEWELL, D. P et al.QJM (Oxford. 1994. Print). 1996, Vol 89, Num 9, pp 713-718, issn 1460-2725Article

The effect of bed rest and operator experience on the incidence of complications after liver biopsySATSANGI, J; IRELAND, A; BLOOM, S et al.European journal of gastroenterology & hepatology. 1993, Vol 5, Num 3, pp 173-176, issn 0954-691XArticle

Nationwide linkage analysis in Scotland to assess mortality following hospital admission for Crohn's disease: 1998-2000A KENNEDY, N; CLARK, D. N; BAUER, J et al.Alimentary pharmacology & therapeutics. 2012, Vol 35, Num 1, pp 142-153, issn 0269-2813, 12 p.Article

Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease : analysis of nationwide experience in Scotland (2004-2008)HO, G. T; MOWAT, A; WATTS, D. A et al.Alimentary pharmacology & therapeutics. 2009, Vol 29, Num 5, pp 527-534, issn 0269-2813, 8 p.Article

The use of adalimumab in the management of refractory Crohn's diseaseHO; SMITH, L; ARNOTT, I. D et al.Alimentary pharmacology & therapeutics. 2008, Vol 27, Num 4, pp 308-315, issn 0269-2813, 8 p.Article

The efficacy of corticosteroid therapy in inflammatory bowel disease : analysis of a 5-year UK inception cohortHO, G.-T; CHIAM, P; DRUMMOND, H et al.Alimentary pharmacology & therapeutics. 2006, Vol 24, Num 2, pp 319-330, issn 0269-2813, 12 p.Article

An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's diseaseARNOTT, I. D. R; MCNEILL, G; SATSANGI, J et al.Alimentary pharmacology & therapeutics. 2003, Vol 17, Num 12, pp 1451-1457, issn 0269-2813, 7 p.Article

Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis : fact or fiction?JAYARAM, H; SATSANGI, J; CHAPMAN, R. W. G et al.Gut. 2001, Vol 48, Num 3, pp 430-434, issn 0017-5749Article

The genetics of inflammatory bowel diseaseSATSANGI, J; JEWELL, D. P; BELL, J. I et al.Gut. 1997, Vol 40, Num 5, pp 572-574, issn 0017-5749Article

Molecular genetics of Crohn's disease : Recent advancesSATSANGI, J; PARKES, M; JEWELL, D. P et al.The European journal of surgery. 1998, Vol 164, Num 12, pp 887-891, issn 1102-4151Conference Paper

Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998―2000 and 2007―2009VENTHAM, N. T; KENNEDY, N. A; DUFFY, A et al.Alimentary pharmacology & therapeutics. 2014, Vol 39, Num 12, pp 1387-1397, issn 0269-2813, 11 p.Article

Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel diseaseNOBLE, C. L; MCCULLOUGH, J; SATSANGI, J et al.Alimentary pharmacology & therapeutics. 2008, Vol 27, Num 7, pp 588-596, issn 0269-2813, 9 p.Article

Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutationsWALKER, L. J; ALDHOUS, M. C; DRUMMOND, H. E et al.Clinical and experimental immunology (Print). 2004, Vol 135, Num 3, pp 490-496, issn 0009-9104, 7 p.Article

Genetic markers may predict disease behavior in patients with ulcerative colitisROUSSOMOUSTAKAKI, M; SATSANGI, J; WELSH, K et al.Gastroenterology (New York, NY. 1943). 1997, Vol 112, Num 6, pp 1845-1853, issn 0016-5085Article